PD-1/PDL-1 Inhibitor Market

Part I. What is the average total number or percentage of advanced stage (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC) patients?

Part II. Among NSCLC patients, what percentage of patients demonstrate Tumor Proportion Score (TPS) equal to or more than 50%?